Harrow, Inc. $HROW Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 56.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 579,520 shares of the company’s stock after purchasing an additional 208,972 shares during the period. Dimensional Fund Advisors LP’s holdings in Harrow were worth $20,428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in HROW. University of Texas Texas AM Investment Management Co. acquired a new stake in Harrow during the 4th quarter worth about $26,000. KBC Group NV acquired a new position in shares of Harrow in the 1st quarter valued at about $31,000. SBI Securities Co. Ltd. lifted its holdings in shares of Harrow by 393.5% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after buying an additional 846 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Harrow in the second quarter worth about $48,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Harrow by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after buying an additional 369 shares during the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Harrow

In other Harrow news, Director Adrienne L. Graves acquired 1,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was acquired at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the transaction, the director directly owned 1,000 shares of the company’s stock, valued at $31,070. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew R. Boll acquired 3,500 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was acquired at an average price of $29.90 per share, with a total value of $104,650.00. Following the completion of the transaction, the chief financial officer directly owned 814,679 shares of the company’s stock, valued at approximately $24,358,902.10. This represents a 0.43% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 12.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Cantor Fitzgerald dropped their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. BTIG Research reissued a “buy” rating and issued a $63.00 price target on shares of Harrow in a report on Tuesday, July 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research report on Monday, July 20th. Finally, Wall Street Zen cut shares of Harrow from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $69.43.

Harrow Stock Up 1.3%

HROW opened at $39.92 on Friday. The company has a fifty day moving average of $40.23 and a two-hundred day moving average of $40.12. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -97.36 and a beta of 0.28. Harrow, Inc. has a fifty-two week low of $28.54 and a fifty-two week high of $54.85. The company has a debt-to-equity ratio of 10.30, a quick ratio of 2.30 and a current ratio of 2.48.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, May 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.31). Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.The firm had revenue of $44.20 million for the quarter, compared to analysts’ expectations of $52.43 million. During the same period in the previous year, the company earned ($0.38) earnings per share. On average, research analysts expect that Harrow, Inc. will post 0.29 earnings per share for the current year.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.